H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 2, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) with a price target of $80.

The analyst noted the company’s recent deal with Novartis as a strong vote of confidence. The deal brings $200 million upfront, which has the potential to lead to a $2 billion milestone. Trucchio highlighted that this deal validates Arrowhead Pharmaceuticals, Inc.’s (NASDAQ:ARWR) approach to treating CNS diseases and adds important funding without diluting shares.

He also likes the positive results from Ionis Pharmaceuticals’ Olezarsen, which supports Arrowhead’s Plozasiran drug. Both drugs target severe hypertriglyceridemia, a condition linked to pancreatitis risk. Trucchio noted that the company stands out by offering quarterly dosing, which may attract patients and doctors.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) develops medicines that silence genes causing difficult diseases using RNA interference.

While we acknowledge the potential of ARWR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.